As of December 2023, Oncomine DxTT can support the detection of six driver genes (EGFR mutation, ALK fusion gene, ROS1 fusion gene, BRAF V 600 E mutation, RET fusion gene, and HER2 mutation) in NSCLC and the determination of indications for treatment with 14 molecularly targeted drugs. This evidence concerns the gene RET and non-small cell lung carcinoma.